Overview

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy

Status:
Terminated
Trial end date:
2020-01-09
Target enrollment:
Participant gender:
Summary
This is a Phase 2/3, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension period to evaluate the safety and efficacy of WVE-210201 (suvodirsen) in ambulatory male pediatric patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping intervention (DYSTANCE 51)
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Wave Life Sciences Ltd.